The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.
Guo has not only been about software and assay development but also about identifying new drugs and new indications for existing drugs for the treatment of lung cancer and breast cancer. Through the ...